VolitionRx Limited Share-based Payment Arrangement, Expense
VolitionRx Limited (VNRX) reported Share-based Payment Arrangement, Expense of $335.44 thousand for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-13.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2024-05-13
- VolitionRx Limited share-based payment arrangement, expense for the quarter ending 2024-03-31 was $335.44K, a 32.16% decline year-over-year.
- VolitionRx Limited share-based payment arrangement, expense for the quarter ending 2023-12-31 was $115.88K.
- VolitionRx Limited share-based payment arrangement, expense for the quarter ending 2023-09-30 was $237.20K.
- VolitionRx Limited share-based payment arrangement, expense for the quarter ending 2023-06-30 was $229.85K.
- VolitionRx Limited share-based payment arrangement, expense for fiscal 2023 was $1.08M.
- VolitionRx Limited share-based payment arrangement, expense for fiscal 2021 was $2.67M, a 91.90% increase from fiscal 2020.
- VolitionRx Limited share-based payment arrangement, expense for fiscal 2020 was $1.39M.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 12 month |
|---|---|---|---|---|
| 2024-03-31 | $335.44K 10-Q · filed 2024-05-13 | $451.32K derived: sum of 2 quarters · filed 2024-05-13 | $688.51K derived: sum of 3 quarters · filed 2024-05-13 | $918.37K derived: sum of 4 quarters · filed 2024-05-13 |
| 2023-12-31 | $115.88K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $353.08K derived: sum of 2 quarters · filed 2024-03-25 | $582.93K derived: sum of 3 quarters · filed 2024-03-25 | $1.08M 10-K · filed 2024-03-25 |
| 2023-09-30 | $237.20K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $467.05K derived: sum of 2 quarters · filed 2023-11-14 | $961.53K 10-Q · filed 2023-11-14 | |
| 2023-06-30 | $229.85K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $724.34K 10-Q · filed 2023-08-14 | ||
| 2023-03-31 | $494.49K 10-Q · filed 2023-05-10 | |||
| 2021-12-31 | $2.67M 10-K · filed 2022-03-30 | |||
| 2020-12-31 | $1.39M 10-K · filed 2022-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |